MBRX - Moleculin Biotech discovers additional anti-SARS-CoV-2 molecule

Moleculin Biotech ([[MBRX]] +3.8%) has discovered a new molecule, named as WP1096, within its antimetabolites portfolio, that has showed significant in vitro antiviral activity against SARS-CoV-2.Though, the company says it is in progress with its lead antiviral candidate WP1122, and is preparing for clinical trials for the treatment of COVID-19.WP1096 and its close analog, WP1097, are structurally slightly different agents within the WP1122 portfolio.The company anticipates to take at least twelve months of development work to assess clinical potential for these new molecules and file an Investigational New Drug ((IND)) application to the US Food and Drug Administration.

For further details see:

Moleculin Biotech discovers additional anti-SARS-CoV-2 molecule